Related Experiment Video

Updated: Feb 28, 2026

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

11.7K

Adenosine: An endogenous mediator in the pathogenesis of gynecological cancer

Amirhossein Bahreyni1, Seyed S Samani2, Elnaz Ghorbani3

  • 1Faculty of Medicine, Department of Clinical Biochemistry and Immunogenetic Research Center, Mazandaran University of Medical Sciences, Sari, Mazandaran, Iran.

Journal of Cellular Physiology
|June 16, 2017
PubMed

Insights

Adenosine signaling in gynecological cancers promotes tumor growth and immune evasion. Inhibiting adenosine pathways, particularly CD39 and CD73, offers a novel therapeutic strategy for ovarian and cervical cancers.

Area of Science:

  • Oncology
  • Cancer Biology
  • Immunology

Background:

  • Extracellular adenosine levels rise in hypoxic tumor microenvironments.
  • Adenosine signaling influences key cancer processes like apoptosis, angiogenesis, metastasis, and immune suppression.
  • Cancer cell responses to adenosine are receptor subtype and cancer-type specific.

Purpose of the Study:

  • To review the role of adenosine in gynecological cancer pathogenesis.
  • To highlight adenosine signaling as a therapeutic target for gynecological cancers.

Main Methods:

  • Literature review of studies on adenosine signaling in gynecological cancers.
  • Analysis of adenosine receptor subtypes and generating enzymes (CD39, CD73) in cancer.

Main Results:

  • Adenosine promotes tumor progression and immune suppression in ovarian and cervical cancers.
  • Inhibition of adenosine signaling, via CD39/CD73, presents a potential therapeutic avenue.
  • Adenosine receptor modulation offers targeted treatment strategies.

Conclusions:

  • Understanding adenosine's role is crucial for managing gynecological cancers.
  • Targeting adenosine pathways, including CD39 and CD73, represents a promising therapeutic strategy.
  • Further research into adenosine signaling can lead to improved patient outcomes.
Keywords:
adenosineadenosine signalinggynecological cancer

More Related Videos

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells09:48

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

Published on: September 12, 2019

8.7K
Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.4K

Related Concept Videos

Oogenesis02:07

Oogenesis

In human women, oogenesis produces one mature egg cell or ovum for every precursor cell that enters meiosis. This process differs in two unique ways from the equivalent procedure of spermatogenesis in males. First, meiotic divisions during oogenesis are asymmetric, meaning that a large oocyte (containing most of the cytoplasm) and minor polar body are produced as a result of meiosis I, and again following meiosis II. Since only oocytes will go on to form embryos if fertilized, this unequal...
70.6K
Adrenergic Receptors: ɑ Subtype01:31

Adrenergic Receptors: ɑ Subtype

Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
3.1K
Endocrine Signaling01:45

Endocrine Signaling

Endocrine cells produce hormones to communicate with remote target cells found in other organs. The hormone reaches these distant areas using the circulatory system. This exposes the whole organism to the hormone but only those cells expressing hormone receptors or target cells are affected. Thus, endocrine signaling induces slow responses from its target cells but these effects also last longer.
68.6K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.5K
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
1.7K
Adrenergic Agonists: Direct-Acting Agents01:30

Adrenergic Agonists: Direct-Acting Agents

Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
3.0K